93 related articles for article (PubMed ID: 10643846)
1. Cost effectiveness analysis of different strategies of management of chronic hepatitis C infection in children.
Sinha M; Das A
Pediatr Infect Dis J; 2000 Jan; 19(1):23-30. PubMed ID: 10643846
[TBL] [Abstract][Full Text] [Related]
2. Treatment for hepatitis C virus in human immunodeficiency virus-infected patients: clinical benefits and cost-effectiveness.
Kuehne FC; Bethe U; Freedberg K; Goldie SJ
Arch Intern Med; 2002 Dec 9-23; 162(22):2545-56. PubMed ID: 12456226
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.
Salomon JA; Weinstein MC; Hammitt JK; Goldie SJ
JAMA; 2003 Jul; 290(2):228-37. PubMed ID: 12851278
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
[TBL] [Abstract][Full Text] [Related]
5. Boceprevir for Chronic Genotype 1 Hepatitis C Virus in the Current Health Care Setting in Greece: A Cost-effectiveness Analysis.
Athanasakis K; Ferrante SA; Kyriopoulos II; Petrakis I; Hill M; Retsa MP; Kyriopoulos J
Clin Ther; 2015 Jul; 37(7):1529-40. PubMed ID: 26031617
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of treatment for hepatitis C in an urban cohort co-infected with HIV.
Campos NG; Salomon JA; Servoss JC; Nunes DP; Samet JH; Freedberg KA; Goldie SJ
Am J Med; 2007 Mar; 120(3):272-9. PubMed ID: 17349451
[TBL] [Abstract][Full Text] [Related]
7. Early Treatment in HCV: Is it a Cost-Utility Option from the Italian Perspective?
Marcellusi A; Viti R; Damele F; Cammà C; Taliani G; Mennini FS
Clin Drug Investig; 2016 Aug; 36(8):661-72. PubMed ID: 27234943
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in Sweden.
Sennfält K; Reichard O; Hultkrantz R; Wong JB; Jonsson D
Scand J Gastroenterol; 2001 Aug; 36(8):870-6. PubMed ID: 11495084
[TBL] [Abstract][Full Text] [Related]
9. Productivity improvements in hepatitis C treatment: impact on efficacy, cost, cost-effectiveness and quality of life.
Lidgren M; Hollander A; Weiland O; Jönsson B
Scand J Gastroenterol; 2007 Jul; 42(7):867-77. PubMed ID: 17558912
[TBL] [Abstract][Full Text] [Related]
10. Cost Effectiveness of Daclatasvir Plus Asunaprevir Therapy for Chinese Patients with Chronic Hepatitis C Virus Genotype 1b.
Liu Y; Wang Z; Tobe RG; Lin H; Wu B
Clin Drug Investig; 2018 May; 38(5):427-437. PubMed ID: 29417464
[TBL] [Abstract][Full Text] [Related]
11. Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs.
Wong JB; Bennett WG; Koff RS; Pauker SG
JAMA; 1998 Dec 23-30; 280(24):2088-93. PubMed ID: 9875876
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of simeprevir in combination with peginterferon and ribavirin for treatment-naïve chronic hepatitis C genotype 1 patients in Japan.
Kuwabara H; Westerhout K; Treur M; Cerri K; Mahlich J; Yatsuhashi H
J Med Econ; 2015; 18(7):502-11. PubMed ID: 25763827
[TBL] [Abstract][Full Text] [Related]
13. Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus infection: a cost-utility analysis from the perspective of the Veterans Affairs Health Care System.
Yeh WS; Armstrong EP; Skrepnek GH; Malone DC
Pharmacotherapy; 2007 Jun; 27(6):813-24. PubMed ID: 17542764
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.
Sullivan SD; Jensen DM; Bernstein DE; Hassanein TI; Foster GR; Lee SS; Cheinquer H; Craxi A; Cooksley G; Klaskala W; Pettit K; Patel KK; Green J
Am J Gastroenterol; 2004 Aug; 99(8):1490-6. PubMed ID: 15307866
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.
Sullivan SD; Craxi A; Alberti A; Giuliani G; De Carli C; Wintfeld N; Patel KK; Green J
Pharmacoeconomics; 2004; 22(4):257-65. PubMed ID: 14974875
[TBL] [Abstract][Full Text] [Related]
16. Interferon treatment for chronic hepatitis B or C infection: costs and effectiveness.
Wong JB
Acta Gastroenterol Belg; 1998; 61(2):238-42. PubMed ID: 9658620
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa.
Fraser I; Burger J; Lubbe M; Dranitsaris G; Sonderup M; Stander T
Pharmacoeconomics; 2016 Apr; 34(4):403-17. PubMed ID: 26666639
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection.
Younossi ZM; Park H; Saab S; Ahmed A; Dieterich D; Gordon SC
Aliment Pharmacol Ther; 2015 Mar; 41(6):544-63. PubMed ID: 25619871
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review.
Shepherd J; Waugh N; Hewitson P
Health Technol Assess; 2000; 4(33):1-67. PubMed ID: 11134916
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C.
Younossi ZM; Singer ME; McHutchison JG; Shermock KM
Hepatology; 1999 Nov; 30(5):1318-24. PubMed ID: 10534357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
